智慧胰岛素笔市场规模 - 按产品类型、连接类型、应用和分销管道 - 区域前景、竞争策略和细分市场预测（截至 2033 年）

预计2033年，全球智慧胰岛素笔市场规模将成长至20,5411万美元，复合年增长率为10.69%。

COVID-19 期间前往医院和糖尿病中心的患者减少，导致智慧胰岛素笔处方减少。此外，配送链问题导致零售店购买困难，销售量减少。与大流行相关的经济放缓使消费者更加重视成本，并减少了昂贵的系留胰岛素笔的市场。

本报告调查了全球智慧胰岛素笔市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业。。

目录

第一章简介

第二章调查方法

第三章执行摘要

第四章市场动态

• 促进因素、抑制因素、机会与挑战分析
• COVID-19 对市场的影响

第五章 市场变数与展望

• SWOT分析
• PESTEL分析
• 波特五力分析
• 热图分析

第六章 竞争状况

• 製造地、销售区域、产品类型分布
• 併购、联盟、产品发布、合作

第七章全球智慧型胰岛素笔市场：依产品

• 全球市占率及预测
• 智慧胰岛素笔
• 传统笔的适配器

第八章全球智慧型胰岛素笔市场：按连接类型

• 全球市占率及预测
• Bluetooth
• USB

第九章全球智慧型胰岛素笔市场：依应用分类

• 全球市占率及预测
• 1型糖尿病
• 2型糖尿病

第10章全球智慧胰岛素笔市场：依通路划分

• 全球市占率及预测
• 医院药房
• 网上销售
• 零售药房
• 糖尿病诊所/中心

第十一章全球智慧胰岛素笔市场预测

• 市场规模/市场占有率

第十二章全球智慧胰岛素笔市场：依产品类型

• 市场规模/市场占有率趋势/预测

第十三章全球智慧胰岛素笔市场：按连结类型

• 市场规模/市场占有率趋势/预测

第14章全球智慧胰岛素笔市场：依应用分类

• 市场规模/市场占有率趋势/预测

第十五章全球智慧胰岛素笔市场：依通路分类

• 市场规模/市场占有率趋势/预测

第十六章全球智慧型胰岛素笔市场：按地区

• 市场规模/市场占有率趋势/预测
• 亚太地区
• 欧洲
• 中东/非洲
• 北美洲
• 拉丁美洲

第十七章 公司简介

• Bigfoot Biomedical
• Diamesco Co. Ltd.
• Eli Lilly and Company
• Emperra GmbH
• Jiangsu Deflu Medical Device Co. Ltd.
• Medtronic plc
• Novo Nordisk A/S
• Pendiq
• Sanofi (Sanofi-Aventis US LLC)
• Ypsomed Holding AG
• 其他的

第十八章简称

第十九章 参考链接

第20章结论

第二十一章 研究范围

Smart Insulin Pens Market Introduction and Overview

According to SPER market research, Smart Insulin Pens Market Size- By Product, By Connectivity Type, By Application, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Smart Insulin Pens Market is predicted to reach USD 2054.11 Million by 2033 with a CAGR of 10.69%.

Smart insulin pens provide an accessible option for exogenous insulin administration and diabetes treatment. It is a reusable injector pen that works with a simple app on a smartphone which allow for wireless data transfer to the app. This intelligent system keeps track of dosages and generates reports, useful notifications, and half-unit doses that are exact. In addition, it alerts patients whenever insulin is about to expire or reaches its temperature spectrum, allowing them to change the cartridge and provide diabetic information to the medical staff as needed.

There was a decrease in the number of prescriptions for smart insulin pens as a result of fewer patients visiting hospitals and diabetic centers during the COVID 19 pandemic. Additionally, the accessibility of these pens at retail stores was disrupted by problems in the delivery chain, which led to a decrease in sales. The pandemic-related economic slowdown made consumers more cost-conscious, which decreased the market for expensive connected insulin pens.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Product, By Connectivity Type, By Application, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Bigfoot Biomedical, Diamesco Co. Ltd., Eli Lilly and Company, Emperra GmbH, Jiangsu Deflu Medical Device Co. Ltd., Medtronic plc, Novo Nordisk A/S, Pendiq, Sanofi (Sanofi-Aventis US LLC), Ypsomed Holding AG, and others.

Smart Insulin Pens Market Segmentation

By Product: Based on the Product, Global Smart Insulin Pens Market is segmented as; Smart Insulin Pens, Adaptors for Conventional Pens

By Application: Based on the Application, Global Smart Insulin Pens Market is segmented as; Type 1 Diabetes, Type 2 Diabetes

By Distribution Channel: Based on the Distribution Channel, Global Smart Insulin Pens Market is segmented as; Hospital Pharmacies, Online Sales, Retail Pharmacies, Diabetes Clinics/Centers

Table of Contents

1.Introduction

• 1.1.Scope of the report
• 1.2.Market segment analysis

2.Research Methodology

• 2.1.Research data source
  • 2.1.1.Secondary Data
  • 2.1.2.Primary Data
  • 2.1.3.SPER's internal database
  • 2.1.4.Premium insight from KOL's
• 2.2.Market size estimation
  • 2.2.1.Top-down and Bottom-up approach
• 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

• 4.1.Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1.Drivers
  • 4.1.2.Restraints
  • 4.1.3.Opportunities
  • 4.1.4.Challenges
• 4.2.COVID-19 Impacts of the Global Smart Insulin Pens Market

5.Market variable and outlook

• 5.1.SWOT Analysis
  • 5.1.1.Strengths
  • 5.1.2.Weaknesses
  • 5.1.3.Opportunities
  • 5.1.4.Threats
• 5.2.PESTEL Analysis
  • 5.2.1.Political Landscape
  • 5.2.2.Economic Landscape
  • 5.2.3.Social Landscape
  • 5.2.4.Technological Landscape
  • 5.2.5.Environmental Landscape
  • 5.2.6.Legal Landscape
• 5.3.PORTER's Five Forces
  • 5.3.1.Bargaining power of suppliers
  • 5.3.2.Bargaining power of buyers
  • 5.3.3.Threat of Substitute
  • 5.3.4.Threat of new entrant
  • 5.3.5.Competitive rivalry
• 5.4.Heat Map Analysis

6.Competitive Landscape

• 6.1.Global Smart Insulin Pens Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Smart Insulin Pens Market

7.Global Smart Insulin Pens Market, By Product (USD Million)

• 7.1.Global Smart Insulin Pens Market Value Share and Forecast, By Product, 2024-2033
• 7.2.Smart Insulin Pens
• 7.3.Adaptors for Conventional Pens

8.Global Smart Insulin Pens Market, By Connectivity Type (USD Million)

• 8.1.Global Smart Insulin Pens Market Value Share and Forecast, By Connectivity Type, 2024-2033
• 8.2.Bluetooth
• 8.3.USB

9.Global Smart Insulin Pens Market, By Application (USD Million)

• 9.1.Global Smart Insulin Pens Market Value Share and Forecast, By Application, 2024-2033
• 9.2.Type 1 Diabetes
• 9.3.Type 2 Diabetes

10.Global Smart Insulin Pens Market, By Distribution Channel (USD Million)

• 10.1.Global Smart Insulin Pens Market Value Share and Forecast, By Distribution Channel, 2024-2033
• 10.2.Hospital Pharmacies
• 10.3.Online Sales
• 10.4.Retail Pharmacies
• 10.5.Diabetes Clinics/Centers

11.Global Smart Insulin Pens Market Forecast, 2020-2033 (USD Million)

• 11.1.Global Smart Insulin Pens Market Size and Market Share

12.Global Smart Insulin Pens Market, By Product Type 2020-2033 (USD Million)

• 12.1.Global Smart Insulin Pens Market Size and Market Share By Product (2020-2026)
• 12.2.Global Smart Insulin Pens Market Size and Market Share By Product (2027-2033)

13.Global Smart Insulin Pens Market, By Connectivity Type, 2020-2033 (USD Million)

• 13.1.Global Smart Insulin Pens Market Size and Market Share By Connectivity Type (2020-2026)
• 13.2.Global Smart Insulin Pens Market Size and Market Share By Connectivity Type (2027-2033)

14.Global Smart Insulin Pens Market, By Application, 2020-2033 (USD Million)

• 14.1.Global Smart Insulin Pens Market Size and Market Share By Application (2020-2026)
• 14.2.Global Smart Insulin Pens Market Size and Market Share By Application (2027-2033)

15.Global Smart Insulin Pens Market, By Distribution Channel, 2020-2033 (USD Million)

• 15.1.Global Smart Insulin Pens Market Size and Market Share By Distribution Channel (2020-2026)
• 15.2.Global Smart Insulin Pens Market Size and Market Share By Distribution Channel (2027-2033)

16.Global Smart Insulin Pens Market, By Region, 2020-2033 (USD Million)

• 16.1.Global Smart Insulin Pens Market Size and Market Share By Region (2020-2026)
• 16.2.Global Smart Insulin Pens Market Size and Market Share By Region (2027-2033)
• 16.3.Asia-Pacific
  • 16.3.1.Australia
  • 16.3.2.China
  • 16.3.3.India
  • 16.3.4.Japan
  • 16.3.5.South Korea
  • 16.3.6.Rest of Asia-Pacific
• 16.4.Europe
  • 16.4.1.France
  • 16.4.2.Germany
  • 16.4.3.Italy
  • 16.4.4.Spain
  • 16.4.5.United Kingdom
  • 16.4.6.Rest of Europe
• 16.5.Middle East and Africa
  • 16.5.1.Kingdom of Saudi Arabia
  • 16.5.2.United Arab Emirates
  • 16.5.3.Rest of Middle East & Africa
• 16.6.North America
  • 16.6.1.Canada
  • 16.6.2.Mexico
  • 16.6.3.United States
• 16.7.Latin America
  • 16.7.1.Argentina
  • 16.7.2.Brazil
  • 16.7.3.Rest of Latin America

17.Company Profile

• 17.1.Bigfoot Biomedical
  • 17.1.1.Company details
  • 17.1.2.Financial outlook
  • 17.1.3.Product summary
  • 17.1.4.Recent developments
• 17.2.Diamesco Co. Ltd.
  • 17.2.1.Company details
  • 17.2.2.Financial outlook
  • 17.2.3.Product summary
  • 17.2.4.Recent developments
• 17.3.Eli Lilly and Company
  • 17.3.1.Company details
  • 17.3.2.Financial outlook
  • 17.3.3.Product summary
  • 17.3.4.Recent developments
• 17.4.Emperra GmbH
  • 17.4.1.Company details
  • 17.4.2.Financial outlook
  • 17.4.3.Product summary
  • 17.4.4.Recent developments
• 17.5.Jiangsu Deflu Medical Device Co. Ltd.
  • 17.5.1.Company details
  • 17.5.2.Financial outlook
  • 17.5.3.Product summary
  • 17.5.4.Recent developments
• 17.6.Medtronic plc
  • 17.6.1.Company details
  • 17.6.2.Financial outlook
  • 17.6.3.Product summary
  • 17.6.4.Recent developments
• 17.7.Novo Nordisk A/S
  • 17.7.1.Company details
  • 17.7.2.Financial outlook
  • 17.7.3.Product summary
  • 17.7.4.Recent developments
• 17.8.Pendiq
  • 17.8.1.Company details
  • 17.8.2.Financial outlook
  • 17.8.3.Product summary
  • 17.8.4.Recent developments
• 17.9.Sanofi (Sanofi-Aventis US LLC)
  • 17.9.1.Company details
  • 17.9.2.Financial outlook
  • 17.9.3.Product summary
  • 17.9.4.Recent developments
• 17.10.Ypsomed Holding AG
  • 17.10.1.Company details
  • 17.10.2.Financial outlook
  • 17.10.3.Product summary
  • 17.10.4.Recent developments
• 17.11.Others

18.List of Abbreviations

19.Reference Links

20.Conclusion

21.Research Scope